Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07755410 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 2 → 19 locations Start date changed from estimate of Aug 2026 to Aug 10, 2026 · Eligibility criteria expanded, about 10 words Show 2 more changesShow less
    • Start date changed from estimate of Aug 2026 to Aug 10, 2026
    • Eligibility criteria expanded, about 10 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Alkermes
10 trials monitored
See 1 trial at risk
ADHD
387 trials monitored
See 23 trials at risk
The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.
Trial Details
NCT Number NCT07755410
Lead Sponsor Alkermes, Inc.
Conditions Attention Deficit Disorder With Hyperactivity (ADHD)
Enrollment 312 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov